News | May 21, 2010

Biodegradable Stent Preserves Mechanical Strength


May 21, 2010 – Results of an in vivo study of 48 porcine arteries implanted with a biodegradable stent showed biodegradation is measurable and begins at the first day of implant. However, high radial strength is maintained during biodegradation.

These results were released this week by Arterial Remodeling Technologies (ART), which is developing bioresorbable coronary polylactic acid polymer stents that promote the natural remodeling of an injured artery after angioplasty.

Previous validating data regarding ART’s next-generation bioresorbable stent approach has been published in the January 2010 special supplement of EuroIntervention. The paper was authored by Antoine Lafont, M.D., Ph.D., Head, Interventional Cardiology Department, Georges Pompidou Hospital, Paris.

The stent is designed to provide an impermanent scaffold that will dismantle and loose its primary mechanical function after three months. This is the period when most experts say is it is necessary to permit the healing process to stabilize the artery following the trauma caused by an angioplasty. The complete resorption of all the polymer is estimated to occur within 18 months.

ART said its stent is designed to have several competitive benefits over existing bioresorbable stents in development. These include faster and smoother resorption, use of a non-crystalline polymer, better stress diffusion, and crack-free expansion. The ART device is designed for conventional balloon stent delivery and meets the market standard of 6 French compatibility.

For more information: www.art-stent.com


Related Content

News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
News | Cardiovascular Clinical Studies

Jan. 13, — A new cohort study among 103,642 adults found that current use of cigars was associated with increased risk ...

Home January 14, 2025
Home
News | Cardiovascular Clinical Studies

Nov. 22, 2024 — BridgeBio Pharma, Inc. recently announced that the U.S. Food and Drug Administration (FDA) approved ...

Home November 25, 2024
Home
News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
Subscribe Now